<DOC>
	<DOCNO>NCT00676650</DOCNO>
	<brief_summary>This study compare safety efficacy sunitinib combination prednisone versus placebo prednisone patient metastatic castration-resistant prostate cancer progress treatment docetaxel-containing chemotherapy regimen . This second-line study .</brief_summary>
	<brief_title>Sunitinib Plus Prednisone In Patients With Metastatic Castration-Resistant Prostate Cancer After Failure Of Docetaxel Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<criteria>Histologically cytologically confirm adenocarcinoma prostate . Progressive , metastatic castrationresistant prostate cancer failure docetaxel chemotherapy ( resistant intolerant ) . Progressive disease base PSA progression , RECIST , positive bone scan . ECOG 0 1 . Prior treatment sunitinib and/or 1 prior chemotherapy regimen metastatic disease set . Chemotherapy within 3 week . Impending complication bone metastasis . Ongoing urinary obstruction . Cardiac dysfunction , QTc &gt; 470 msec . CNS involvement .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Docetaxel-refractory mCRPC</keyword>
	<keyword>Second-line treatment sunitinib prednisone</keyword>
</DOC>